TWD 744.0
(-0.67%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 1.74 Billion TWD | 75.86% |
2022 | 990.59 Million TWD | 58.3% |
2021 | 625.78 Million TWD | 30.97% |
2020 | 477.8 Million TWD | 56.35% |
2019 | 305.59 Million TWD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 1.2 Billion TWD | 96.86% |
2024 Q1 | 613.94 Million TWD | 9.44% |
2023 Q2 | 377.72 Million TWD | -0.15% |
2023 Q4 | 561.01 Million TWD | 31.98% |
2023 FY | 1.74 Billion TWD | 75.86% |
2023 Q1 | 378.29 Million TWD | -38.24% |
2023 Q3 | 425.07 Million TWD | 12.54% |
2022 Q3 | 91.43 Million TWD | 0.0% |
2022 FY | 990.59 Million TWD | 58.3% |
2022 Q4 | 612.47 Million TWD | 569.87% |
2021 FY | 625.78 Million TWD | 30.97% |
2020 FY | 477.8 Million TWD | 56.35% |
2019 FY | 305.59 Million TWD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Grape King Bio Ltd | 6.03 Billion TWD | 71.154% |
Standard Chem & Pharm CO., LTD. | 1.46 Billion TWD | -18.848% |
Maywufa Company Ltd. | 854.37 Million TWD | -103.904% |
ScinoPharm Taiwan, Ltd. | 901.49 Million TWD | -93.245% |
Lotus Pharmaceutical Co., Ltd. | 4.48 Billion TWD | 61.121% |
LIWANLI Innovation Co., Ltd. | 54.86 Million TWD | -3075.189% |
YungShin Global Holding Corporation | 2.04 Billion TWD | 14.924% |
PhytoHealth Corporation | 67.64 Million TWD | -2475.431% |
SCI Pharmtech, Inc. | 190.02 Million TWD | -816.783% |
Formosa Laboratories, Inc. | 1.24 Billion TWD | -39.552% |
PharmaEssentia Corporation | 4.49 Billion TWD | 61.244% |